This edition of the HDYO Research Video Series focuses on the HDBuzz article analyzing the update from PTC Therapeutics. PTC shared 12 month data from the PIVOT-HD trial, testing the oral HTT lowering drug PTC-518. While designed to assess safety, they shared encouraging results that the drug showed promising signs for biomarkers and some clinical metrics.
The Research Video Series is sponsored by Roche, Sage Therapeutics, Teva Pharmaceuticals, uniQure, Wave Life Sciences, Griffin Foundation and Neurocrine Biosciences.